Additionally, patients with low SPRYD4 expression also had poor OS in other cancer types including kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), pancreatic adenocarcinoma (PAAD) and lung squamous cell carcinoma (LUSC) (Fig. S2). Here, SPRYD4 is linked to pancreatic adenocarcinoma.